Relation Partners with GSK to Develop Therapies Targeting Fibrotic Diseases and Osteoarthritis
Shots:
- Relation has entered into a strategic multi-program partnerships with GSK for the development of novel therapies targeting fibrotic diseases and osteoarthritis
- As per both the agreements, GSK will pay $45M upfront ($15M in equity), $63M success-based collaboration payments, an average $200M milestones per target plus net-sales based tiered royalties
- Relation will use its Lab-in-the-Loop platform to analyze data from observational studies, integrating genetics, single-cell multi-omics, functional assays & ML to discover disease targets. GSK gains global rights to develop & commercialize resulting targets
Ref: Relation & GSK | Image: Relation & GSK
Related News:- GSK Reports the US FDA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
